Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed) | RFA HG 23 048

Opportunity Information: Apply for RFA HG 23 048

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed) is a National Institutes of Health funding opportunity (RFA-HG-23-048; CFDA 93.172) designed to spark practical, implementation-focused research in genomic medicine. The central goal is to support innovative projects that improve understanding of when, where, and how genomic information and genomic technologies should be used and shared in routine clinical care. A major emphasis is ensuring that genomic medicine works for everyone, regardless of racial or ethnic background or socioeconomic status, which makes questions about equitable access, usability, workflow integration, communication, trust, and appropriate data sharing especially relevant.

This opportunity uses the NIH R03 mechanism, which is built for small, time-limited studies that do not require large budgets or long project periods. It is particularly suited for pilot studies, feasibility work, secondary analyses of existing datasets, small self-contained projects, and early development or refinement of research methods relevant to genomic medicine implementation. Because R03 awards are meant to move ideas forward quickly, the application is not expected to include extensive preliminary data or long background sections. Reviewers are instructed to focus heavily on the strength of the conceptual approach, how innovative the proposed work is, and whether the project can meaningfully advance knowledge about implementing and sharing genomics in real clinical settings. Applicants can justify their approach using published literature, existing data sources, or investigator-generated information when available, but preliminary data are explicitly not required.

As indicated in the title, clinical trials are not allowed under this NOFO, so proposed studies should not be designed as prospective interventions that assign participants to conditions to evaluate health outcomes in the way NIH defines clinical trials. Instead, projects typically fit into categories such as observational research, workflow and implementation analyses, studies of real-world use patterns, evaluation of barriers and facilitators, development of tools or methods, ethical/legal/social implication analyses tied to clinical implementation, or analyses of already-collected clinical or genomic data to answer questions about best practices for integration and sharing.

Eligibility is broad and includes many types of U.S.-based organizations: state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education institutions in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other eligible entities. The NOFO also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign institutions (non-U.S. entities) are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply; however, foreign components may be allowed when they meet the NIH definition under the NIH Grants Policy Statement, which generally means a discrete portion of the project can be conducted abroad if it is well justified and permitted under NIH rules.

The posted award ceiling is $500,000, and the original closing date listed is 2025-02-11. Overall, this NOFO is aimed at helping teams quickly test or refine promising ideas that can make genomic medicine implementation more effective, more scalable, and more equitable, while keeping the scope tightly focused and achievable with limited resources and within a short timeframe.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
• This funding opportunity was created on 2023-11-06.
• Applicants must submit their applications by 2025-02-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HG 23 048

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: